Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Semin Oncol 2015 Dec;42(6):849-62

Date

11/29/2015

Pubmed ID

26615130

Pubmed Central ID

PMC4663016

DOI

10.1053/j.seminoncol.2015.09.023

Scopus ID

2-s2.0-84962305085   30 Citations

Abstract

Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled tumor cell proliferation and survival, thus providing a rational therapeutic target for the treatment of many cancers. While Raf, MEK1/2, and ERK1/2 are equally important targets for the design of therapeutic small molecular weight inhibitors, the effort to develop MEK1/2-specific inhibitors has been greatly successful. Particularly, MEK1/2 have been relatively advantageous for the design of highly selective adenosine triphosphate (ATP)-noncompetitive inhibitors. Indeed, a plethora of highly selective and potent MEK1/2 inhibitors are now available and many of those inhibitors have been evaluated for their therapeutic potential. Herein, we review different MEK1/2 inhibitors that have been studied for their inhibitory mechanisms and therapeutic potential in cancer. Some of the key structural features of MEK1/2 that are important for the efficacy of these inhibitors are also discussed. In addition, we discuss current challenges and future prospective in using these advanced MEK1/2 inhibitors for cancer therapy.

Author List

Wu PK, Park JI

Authors

Jong-In Park PhD Professor in the Biochemistry department at Medical College of Wisconsin
Pui Kei Wu PhD Instructor in the Biochemistry department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Drug Resistance, Neoplasm
Humans
MAP Kinase Kinase 1
MAP Kinase Kinase 2
Molecular Targeted Therapy
Neoplasms
Protein Kinase Inhibitors
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a